Stem Cell Therapy for Parkinson's Disease: Past, Present and Future
DOI:
https://doi.org/10.37591/rrjon.v9i1.664Abstract
Parkinson’s disease (PD) is one of the most common chronic progressive nervous system disorders of aging. Cell degeneration and death of dopamine neurons (DA neurons) in the substantial nigra, is the underlying feature of PD. Genetic studies showed much about the physiological processes associated with this disease. Replacing the cells lost by injury or disease has become a central idea aiming at the development of novel therapy for neurodegenerative diseases. Dopamine replacement and electrical stimulation of the affected brain areas are used currently as most common therapies. Even though both the techniques work well in treating patients, the progression of disease cannot be blocked. The advancement in stem cell technology is attracting interest and discussion for the treatment of PD using different types of stem cells. Human embryonic stem cells, neural stem cells, derived from fetal brain issues, induced pluripotent stem cells (iPSCs) and directly induced dopamine neurons are the most common cell sources used currently. Here in this review, we assess the advancement in various cell sources and the challenges ahead for developing affordable cells which can be produced in large scale and may be used in clinical settings in the treatment of PD effectively.
Keywords: Parkinson’s disease, iPSCs, transplantation, pluripotent stem cells, gene therapy, cell therapy, dopaminergic neuron
Cite this Article
Muluken Fekadie Zerihun, Gebreselassie Addisu Tilaye. Stem Cell Therapy for Parkinson's Disease: Past, Present and Future. Research and Reviews: Journal of Neuroscience. 2019; 9(1): 1–12p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
